OTC Markets OTCPK - Delayed Quote USD

Innovent Biologics, Inc. (IVBXF)

Compare
4.5294
0.0000
(0.00%)
At close: January 10 at 3:00:00 PM EST
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for IVBXF

Recent News: IVBXF

View More
High Growth Tech Stocks Innovent Biologics And 2 Other Promising Picks

High Growth Tech Stocks Innovent Biologics And 2 Other Promising Picks
Simply Wall St. 3 days ago
Innovent to Participate and Present at the 43rd Annual J.P. Morgan Healthcare Conference

Innovent to Participate and Present at the 43rd Annual J.P. Morgan Healthcare Conference
PR Newswire 6 days ago
Innovent Announces Second New Drug Application of DOVBLERON ® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) was Approved by China's National Medical Products Administration

Innovent Announces Second New Drug Application of DOVBLERON ® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) was Approved by China's National Medical Products Administration
PR Newswire 9 days ago
Innovent and Roche link on lung cancer therapy development

Innovent and Roche link on lung cancer therapy development
Pharmaceutical Technology 9 days ago
Innovent Enters into Exclusive Global License Agreement with Roche for Novel DLL3 Antibody Drug Conjugate

Innovent Enters into Exclusive Global License Agreement with Roche for Novel DLL3 Antibody Drug Conjugate
PR Newswire 10 days ago
Mankind Pharma and Innovent partner for Sintilimab commercialisation in India

Mankind Pharma and Innovent partner for Sintilimab commercialisation in India
Pharmaceutical Technology 15 days ago
Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration
PR Newswire 22 days ago
Innovent and Lilly Expand Collaboration Through Agreement on Commercialization Rights for Jaypirca® (pirtobrutinib) in Mainland China

Innovent and Lilly Expand Collaboration Through Agreement on Commercialization Rights for Jaypirca® (pirtobrutinib) in Mainland China
PR Newswire 27 days ago
Exploring Three High Growth Tech Stocks For Potential Expansion

Exploring Three High Growth Tech Stocks For Potential Expansion
Simply Wall St. last month
Innovent Presents Updated Data From Innovative Anti-CLDN18.2 ADC (IBI343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the ESMO Asia Congress 2024

Innovent Presents Updated Data From Innovative Anti-CLDN18.2 ADC (IBI343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the ESMO Asia Congress 2024
PR Newswire last month
Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer

Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer
PR Newswire last month
View More

Related Tickers

SHJBF Shanghai Junshi Biosciences Co., Ltd.
1.9700
+58.87%
 
BRAXF Braxia Scientific Corp.
0.0020
+33.33%
 
DMYD-B.ST Diamyd Medical AB (publ)
17.14
-5.20%
 
AVBP ArriVent BioPharma, Inc.
24.88
-7.37%
 
RLYB Rallybio Corporation
0.9400
-5.63%
 
LVTX LAVA Therapeutics N.V.
0.9758
-5.26%
 
LXEO Lexeo Therapeutics, Inc.
6.39
-6.30%
 
VIGL Vigil Neuroscience, Inc.
1.7900
-2.72%
 
ADVM Adverum Biotechnologies, Inc.
4.2700
-5.53%
 
TELO Telomir Pharmaceuticals, Inc.
4.1100
-4.42%